Rituximab | sciencenewsnet.in

Breaking News

Three Johns Hopkins Medicine Researchers Named Fellows of the American Association for the Advancement of Science

Glaucoma Research Foundation establishes Strategic Advisory Council

1 in 5 milk samples from grocery stores test positive for bird flu. Why the FDA says it’s still safe to drink

‘Fallout’ success: video game nostalgia spans multiple media, explains expert

Scientists are shaking up lithium extraction with a different kind of chemistry

ORNL’s Curran named Fellow of SAE, ASME

Computer Scientists Unveil Novel Attacks on Cybersecurity

Interplay between mesenchymal stem cells and macrophages: Promoting bone tissue repair

Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing

27 Apr, 2024

Patients taking Rituximab Could Benefit from Third COVID-19 Vaccine Dose

November 1, 2021 sarah JonasResearch Results

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.

Ultra-Low Dose Rituximab Controls Disease Activity for Most RA Patients in New Study

November 1, 2021 sarah JonasResearch Results

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows the majority of rheumatoid arthritis patients on an ultra-low dose of rituximab maintained low disease activity for up to 4 years, and rarely needed to switch to other biologic drugs.